Cirmtuzumab

Drug Profile

Cirmtuzumab

Alternative Names: UC-961

Latest Information Update: 19 Dec 2016

Price : $50

At a glance

  • Originator University of California, San Diego
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Receptor protein-tyrosine kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Chronic lymphocytic leukaemia

Most Recent Events

  • 06 Dec 2016 Interim adverse events, PK, PD and efficacy data from a phase I trial in Chronic lymphocytic leukaemia (Second line therapy or greater, Refractory metastatic disease) presented at the 58th Annual Meeting of the American Society of Haematology (ASH-2016)
  • 06 Dec 2016 Pharmacodynamics data from preclinical studies in Chronic lymphocytic leukaemia presented at the 58th Annual Meeting of the American Society of Haematology (ASH-2016 (9208453)
  • 01 Jun 2016 Tokalas, Inc. has merged with Oncternal Therapeutics to form Oncternal Therapeutics, Inc.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top